Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alligator Bioscience AB ( (SE:ATORX) ) has shared an update.
Alligator Bioscience announced the publication of Phase 1 trial data for mitazalimab in Nature Communications, showcasing its potential in treating metastatic pancreatic ductal adenocarcinoma. The study demonstrated significant immunological effects, including reduced tumor fibrosis and increased T-cell infiltration, supporting mitazalimab’s role in reshaping the tumor microenvironment. These findings reinforce the drug’s potential in combination therapies for hard-to-treat cancers, aligning with Alligator’s broader clinical strategy.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company that develops clinical-stage tumor-directed antibody drugs focusing on the CD40 receptor. Their approach aims to prime T cells and reverse the immunosuppressive nature of the tumor microenvironment, offering potential benefits for cancer patients across various cancer types. The company is listed on Nasdaq Stockholm and is headquartered in Lund, Sweden.
YTD Price Performance: -95.86%
Average Trading Volume: 1,226,699
Technical Sentiment Signal: Sell
Current Market Cap: SEK38.21M
See more data about ATORX stock on TipRanks’ Stock Analysis page.